{"pmid":32351040,"title":"COVID-19 in kidney transplant recipients.","text":["COVID-19 in kidney transplant recipients.","There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals.","Am J Transplant","Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P","32351040"],"abstract":["There is minimal information on COVID-19 in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for SARS-CoV-2 by PCR, and 9 were admitted. The median age was 57 (IQR 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common CXR and CT abnormality was multifocal patchy opacities. 3 patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. 9 patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine (HCQ) and azithromycin. 3 patients died (30%), five (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of non-transplant individuals."],"journal":"Am J Transplant","authors":["Nair, Vinay","Jandovitz, Nicholas","Hirsch, Jamie S","Nair, Gayatri","Abate, Mersema","Bhaskaran, Madhu","Grodstein, Elliot","Berlinrut, Ilan","Hirschwerk, David","Cohen, Stuart L","Davidson, Karina W","Dominello, Andrew J","Osorio, Gabrielle A","Richardson, Safiya","Teperman, Lewis W","Molmenti, Ernesto P"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32351040","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15967","locations":["Caucasian","myalgia","Leukopenia"],"e_drugs":["Tacrolimus","Azithromycin","Hydroxychloroquine","Prednisone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495707512832,"score":9.490897,"similar":[{"pmid":32471001,"title":"COVID-19 in elderly kidney transplant recipients.","text":["COVID-19 in elderly kidney transplant recipients.","The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate.","Am J Transplant","Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio","32471001"],"abstract":["The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12(th) until April-4(th) 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged >/=65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7 days. All presented with fever and all but one with pneumonia. Up to 33% showed renal graft dysfunction. At infection diagnosis, mTOR inhibitors or mycophenolate were withdrawn. Tacrolimus was withdrawn in 70%. The main treatment combination was hydroxychloroquine and azithromycin. A subset of patients was treated with anti-retroviral and tocilizumab. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Although a higher respiratory rate was observed at admission in nonsurvivors, symptoms at presentation were similar between both groups. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests. COVID-19 is frequent among the elderly KT population and associates a very early and high mortality rate."],"journal":"Am J Transplant","authors":["Crespo, Marta","Jose Perez-Saez, Maria","Redondo-Pachon, Dolores","Llinas-Mallol, Laura","Montero, Maria Milagro","Villar, Judith","Arias-Cabrales, Carlos","Buxeda, Anna","Burballa, Carla","Vazquez, Susana","Lopez, Thais","Moreno, Fatima","Mir, Marisa","Outon, Sara","Sierra, Adriana","Collado, Silvia","Barrios, Clara","Rodriguez, Eva","Sans, Laia","Barbosa, Francesc","Cao, Higini","Arenas, Maria Dolores","Guerri-Fernandez, Roberto","Horcajada, Juan Pablo","Pascual, Julio"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32471001","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/ajt.16096","locations":["obese"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668167109982552064,"score":270.6492},{"pmid":32354634,"pmcid":"PMC7142691","title":"A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","text":["A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","Kidney Int","Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco","32354634"],"abstract":["The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality."],"journal":"Kidney Int","authors":["Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354634","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.04.002","keywords":["acute kidney injury","inflammation","tocilizumab","transplantation"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495273402368,"score":242.57451},{"pmid":32402056,"title":"Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.","text":["Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.","Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression. Objective: To describe the characteristics, treatment, and outcomes of recipients of HT with COVID-19. Design, Setting, and Participants: This case series from a single large academic heart transplant program in New York, New York, incorporates data from between March 1, 2020, and April 24, 2020. All recipients of HT followed up by this center who were infected with COVID-19 were included. Interventions: Heart transplant and a confirmed diagnosis of COVID-19. Main Outcomes and Measures: The primary measure was vital status at end of study follow-up. Secondary measures included patient characteristics, laboratory analyses, changes to immunosuppression, and treatment administered for COVID-19. Results: Twenty-eight patients with HT received a confirmed diagnosis of COVID-19. The median age was 64.0 (interquartile range [IQR], 53.5-70.5) years, 22 (79%) were men, and the median time from HT was 8.6 (IQR, 4.2-14.5) years. Comorbid conditions included hypertension in 20 patients (71%), diabetes in 17 patients (61%), and cardiac allograft vasculopathy in 16 patients (57%). Twenty-two participants (79%) were admitted for treatment, and 7 (25%) required mechanical ventilation. Most (13 of 17 [76%]) had evidence of myocardial injury (median high-sensitivity troponin T, 0.055 [IQR, 0.0205-0.1345] ng/mL) and elevated inflammatory biomarkers (median peak high-sensitivity C-reactive protein, 11.83 [IQR, 7.44-19.26] mg/dL; median peak interleukin 6, 105 [IQR, 38-296] pg/mL). Among patients managed at the study institution, mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (18 patients [78%]), high-dose corticosteroids (8 patients [47%]), and interleukin 6 receptor antagonists (6 patients [26%]). Overall, 7 patients (25%) died. Among 22 patients (79%) who were admitted, 11 (50%) were discharged home, 4 (18%) remain hospitalized at the end of the study, and 7 (32%) died during hospitalization. Conclusions and Relevance: In this single-center case series, COVID-19 infection was associated with a case fatality rate of 25% in recipients of HT. Immunosuppression was reduced in most of this group of patients. Further study is required to evaluate the optimal approach to management of COVID-19 infection in the HT population.","JAMA Cardiol","Latif, Farhana","Farr, Maryjane A","Clerkin, Kevin J","Habal, Marlena V","Takeda, Koji","Naka, Yoshifumi","Restaino, Susan","Sayer, Gabriel","Uriel, Nir","32402056"],"abstract":["Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression. Objective: To describe the characteristics, treatment, and outcomes of recipients of HT with COVID-19. Design, Setting, and Participants: This case series from a single large academic heart transplant program in New York, New York, incorporates data from between March 1, 2020, and April 24, 2020. All recipients of HT followed up by this center who were infected with COVID-19 were included. Interventions: Heart transplant and a confirmed diagnosis of COVID-19. Main Outcomes and Measures: The primary measure was vital status at end of study follow-up. Secondary measures included patient characteristics, laboratory analyses, changes to immunosuppression, and treatment administered for COVID-19. Results: Twenty-eight patients with HT received a confirmed diagnosis of COVID-19. The median age was 64.0 (interquartile range [IQR], 53.5-70.5) years, 22 (79%) were men, and the median time from HT was 8.6 (IQR, 4.2-14.5) years. Comorbid conditions included hypertension in 20 patients (71%), diabetes in 17 patients (61%), and cardiac allograft vasculopathy in 16 patients (57%). Twenty-two participants (79%) were admitted for treatment, and 7 (25%) required mechanical ventilation. Most (13 of 17 [76%]) had evidence of myocardial injury (median high-sensitivity troponin T, 0.055 [IQR, 0.0205-0.1345] ng/mL) and elevated inflammatory biomarkers (median peak high-sensitivity C-reactive protein, 11.83 [IQR, 7.44-19.26] mg/dL; median peak interleukin 6, 105 [IQR, 38-296] pg/mL). Among patients managed at the study institution, mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (18 patients [78%]), high-dose corticosteroids (8 patients [47%]), and interleukin 6 receptor antagonists (6 patients [26%]). Overall, 7 patients (25%) died. Among 22 patients (79%) who were admitted, 11 (50%) were discharged home, 4 (18%) remain hospitalized at the end of the study, and 7 (32%) died during hospitalization. Conclusions and Relevance: In this single-center case series, COVID-19 infection was associated with a case fatality rate of 25% in recipients of HT. Immunosuppression was reduced in most of this group of patients. Further study is required to evaluate the optimal approach to management of COVID-19 infection in the HT population."],"journal":"JAMA Cardiol","authors":["Latif, Farhana","Farr, Maryjane A","Clerkin, Kevin J","Habal, Marlena V","Takeda, Koji","Naka, Yoshifumi","Restaino, Susan","Sayer, Gabriel","Uriel, Nir"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402056","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1001/jamacardio.2020.2159","locations":["New York","New York","calcineurin","optimal"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666714494896701441,"score":238.65303},{"pmid":32400931,"title":"Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.","text":["Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.","Coronavirus disease 2019 (COVID-19) pandemic sweeps the globe. The information regarding the kinetic changes of SARS-CoV-2 in immunosuppressed patients is unclear. Herein, we present a case of prolonged viral shedding in a transplant patient with COVID-19 pneumonia. A 49-year-old male kidney recipient was admitted to the hospital on February 7, 2020, for fever and fatigue. He was a permanent resident in Wuhan, China, and began having symptoms on January 29 (day 1 of illness). His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination.","Am J Transplant","Zhang, Man","Zhang, Jing","Shi, Huibo","Liu, Bin","Zeng, Fanjun","32400931"],"abstract":["Coronavirus disease 2019 (COVID-19) pandemic sweeps the globe. The information regarding the kinetic changes of SARS-CoV-2 in immunosuppressed patients is unclear. Herein, we present a case of prolonged viral shedding in a transplant patient with COVID-19 pneumonia. A 49-year-old male kidney recipient was admitted to the hospital on February 7, 2020, for fever and fatigue. He was a permanent resident in Wuhan, China, and began having symptoms on January 29 (day 1 of illness). His maintenance immunosuppressive regime was consisted of tacrolimus (TAC, 1mg twice a day, orally), mycophenolate mofetil (MMF, 0.5g twice a day, orally) and prednisone (Pred, 5mg daily, orally) triple combination."],"journal":"Am J Transplant","authors":["Zhang, Man","Zhang, Jing","Shi, Huibo","Liu, Bin","Zeng, Fanjun"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400931","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.15996","locations":["Wuhan","China","Pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Tacrolimus","Prednisone","Mycophenolic Acid"],"topics":["Case Report"],"weight":1,"_version_":1666865855045042178,"score":232.23807},{"pmid":32330343,"title":"COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","text":["COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.","Am J Transplant","Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C","32330343"],"abstract":["Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients."],"journal":"Am J Transplant","authors":["Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330343","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15941","locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","Azithromycin","tocilizumab","Steroids"],"topics":["Treatment"],"weight":1,"_version_":1666138494683054081,"score":217.15279}]}